Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis

IF 4.5 3区 医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2024-09-25 DOI:10.1016/j.vaccine.2024.126385
Célya Danzelle , Patricia Cunha , Pablo Gomes Noleto , Florence B. Gilbert , Kamila Reis Santos , Christophe Staub , Anne Pinard , Alain Deslis , Sarah Barbey , Pierre Germon , Johan-Owen De Craene , Pascal Rainard , Marc Blondel , Rodrigo Prado Martins
{"title":"Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis","authors":"Célya Danzelle ,&nbsp;Patricia Cunha ,&nbsp;Pablo Gomes Noleto ,&nbsp;Florence B. Gilbert ,&nbsp;Kamila Reis Santos ,&nbsp;Christophe Staub ,&nbsp;Anne Pinard ,&nbsp;Alain Deslis ,&nbsp;Sarah Barbey ,&nbsp;Pierre Germon ,&nbsp;Johan-Owen De Craene ,&nbsp;Pascal Rainard ,&nbsp;Marc Blondel ,&nbsp;Rodrigo Prado Martins","doi":"10.1016/j.vaccine.2024.126385","DOIUrl":null,"url":null,"abstract":"<div><div>Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine <em>in vitro, ex vivo,</em> and <em>in vivo</em> approaches to evaluate the potential of the yeast <em>Saccharomyces cerevisiae</em> as a platform for novel vaccines against bovine mastitis. We demonstrate that <em>S. cerevisiae</em> is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of <em>S. cerevisiae</em> antigens are necessary for the development of successful vaccine candidates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24010673","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine in vitro, ex vivo, and in vivo approaches to evaluate the potential of the yeast Saccharomyces cerevisiae as a platform for novel vaccines against bovine mastitis. We demonstrate that S. cerevisiae is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of S. cerevisiae antigens are necessary for the development of successful vaccine candidates.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将酿酒酵母菌作为牛乳腺炎疫苗接种平台
乳腺炎是乳制品行业的一个主要问题。尽管进行了多次尝试,但现有乳腺炎疫苗的功效有限,原因在于它们无法引发强大的细胞介导免疫。最近,人们发现酵母是一种很有前景的抗原载体,能够诱导 T 细胞应答,超越了传统佐剂疫苗诱导的抗体偏倚机制。在本研究中,我们将体外、体内和体外方法结合起来,评估了酿酒酵母作为新型牛乳腺炎疫苗平台的潜力。我们证明酵母菌可安全用于奶牛的肌肉注射和乳房内免疫。接种疫苗后,针对酵母平台的 IFNγ 和 IL-17 反应显著增加,但针对疫苗抗原的反应却没有增加。这些观察结果表明,要开发出成功的候选疫苗,就必须采取策略来平衡麦角酵母菌抗原的免疫优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccine
Vaccine 医学-免疫学
CiteScore
8.70
自引率
5.50%
发文量
992
审稿时长
131 days
期刊介绍: Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
期刊最新文献
Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices Corrigendum to “Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection” [Vaccine 42 (1–12) (2024) 126325] Cost effectiveness analysis of rotavirus vaccination in Indonesia Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1